Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+melanoma

5 Results

Sort By:

Compositions and Methods for Treating Melanoma--Further Modifications

Unmet NeedTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially due to the ease with which they can be manufactured....

Published: 6/27/2024 | Inventor(s): Richard Markham, James Gordy

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Melanoma, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines

A Molecular Mechanism for the Activation of Mutant TERT by the BRAF V600E/MAP Kinase Pathway

Unmet NeedThe oncogenic duet of BRAF V600E and TERT promoter mutations occurs in approximately 7-8% of papillary thyroid cancer (PTC) cases and 20-50% of melanoma cases. These percentages also correspond to the proportion of cases with the poorest clinical and pathological outcomes. When mutations in either of these oncogenes alone are present, only...

Published: 6/27/2024 | Inventor(s): Michael Xing, Rengyun Liu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Clinical and Disease Specializations > Oncology > Melanoma

JHU REF: C12704 - NOVEL STRATEGIES TO OVERCOME MELANOMA DRUG RESISTANCE

Invention novelty: Novel methods for predicting melanoma resistance to BRAF/MEK inhibitors and for treating melanoma cancer patients.Value Proposition:An estimated 76,690 new cases of invasive melanoma will be diagnosed in the US in 2013 and an estimated 9,480 people will die of melanoma in 2013. Although BRAF and MEK inhibitors have proven clinical...

Published: 6/27/2024 | Inventor(s): Dingxie Liu, Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Melanoma, Pharmakodynamic Biomarker, Skin Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

Artificial Cells of Defined and Dynamic Size and Shape

Invention novelty: This invention is polymer based artificial cells that can be functionalized to induce an immune response or act as stem cells. Value PropositionAntibiotics are the most commonly used treatment for infectious diseases. Unfortunately, overuse and misuse of these compounds is fairly common, and results in the development of antibiotic...

Published: 6/27/2024 | Inventor(s): Joel Sunshine, Karlo Perica, Jonathan Schneck, Jordan Green

Keywords(s): Cancers, Cell Signaling, Cell Therapy, Discovery/Research Tools, Disease Indication, Melanoma, Molecular Switches/Receptors, Research Reagent, Single, Skin Cancer, Therapeutic Matter, Therapeutics, Therapy Type, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Melanoma

MART-1 Phosphopeptides Restricted by HLA-DR1 for use as Melanoma Vaccines

C10691: Novel Peptides as a Melanoma Vaccine Value Proposition: • Phosphopeptides for use as vaccines for therapy and prevention of melanoma • Phosphopeptides for robust, diverse, and long-lasting anti-tumor immunity • Specific activity against whole melanoma tumor cells in vitro • Stand alone therapy/Combination Therapy •...

Published: 6/27/2024 | Inventor(s): Donald Hunt, Florence Depontieu, Angela Zarling, Victor Engelhard, Jeffrey Shabanowitz, Jie Qian, Suzanne Topalian

Keywords(s): Biologics, Cancers, Disease Indication, Immunotherapy, Melanoma, Peptide, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities